Physician profile
Jonathan D Salisbury
NPI 1124319389
$1,683.91
in general payments reported to CMS, 2019-2025
20 companies · $544 in 2025
The $544 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $408 · 2024: $616 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $315.87 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $229.39 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $224.66 | 2023-2025 | |
| Sanofi Pasteur INC. | $193.29 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $129.49 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $95.56 | 2022-2025 | Doc Band |
| Neos Therapeutics, LP | $79.96 | 2023-2025 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $77.90 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $71.93 | 2023-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $71.89 | 2024 | |
| Verrica Pharmaceuticals INC. | $37.84 | 2025 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $23.00 | 2025 | Neffy |
| Seqirus USA INC | $19.16 | 2025 | Flucelvax |
| Sobi, INC | $18.30 | 2023 | |
| Kyowa Kirin, INC. | $17.96 | 2024 | Crysvita |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $17.51 | 2025 | Biofire Spotfire Control Station |
| Vertical Pharmaceuticals, LLC | $16.77 | 2024 | Methylphenidate Hydrochloride |
| Phadia US INC. | $15.12 | 2025 | Immunocap |
| Novo Nordisk INC | $14.89 | 2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $13.42 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Salisbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.